Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | KRAS | P01116 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | BCR | P11274 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16637220 | 0.84 | KRAS (0.44) | HRH4MEN1KMT2ASMN1; SMN2KRAS | |
| SCHEMBL22631299 | 0.80 | NPY5R (0.44) | HRH4MEN1KMT2AHSD17B10NPY5R | |
| SCHEMBL22631427 | 0.79 | KRAS (0.46) | MEN1KMT2ASMN1; SMN2KRASNPY5R | |
| SCHEMBL16637591 | 0.78 | TLR9 (0.50) | MEN1KMT2AKRAS | |
| SCHEMBL16637903 | 0.78 | KRAS (0.36) | HRH4MEN1KMT2ASMN1; SMN2KRAS | |
| SCHEMBL22028936 | 0.74 | TLR9 (0.50) | MEN1KMT2AKRAS | |
| SCHEMBL30826956 | 0.74 | TLR9 (0.50) | MEN1KMT2AKRAS | |
| SCHEMBL16636864 | 0.73 | CSNK2A1 (0.37) | HRH4MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL16637083 | 0.72 | EIF2AK4 (0.39) | KRASL3MBTL1ALDH1A1 | |
| SCHEMBL16636985 | 0.72 | NR1H2 (0.47) | MEN1KMT2AKRASL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | HRH4 1070/4885MEN1 188/4885KMT2A 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.